SynthesisAnnals of hematology2026
Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review.
Synthesis in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe aplastic anemia (SAA) is a rare bone marrow failure disorder with high morbidity and mortality, particularly in patients ineligible for hematopoietic stem cell transplantation. While immunosuppressive therapy (IST) remains standard first-line treatment, a significant proportion of patients fail to respond or relapse. Thrombopoietin receptor agonists (TPO-RAs) have emerged as promising therapeutic options to enhance hematopoiesis. Among them, romiplostim has shown increasing efficacy across multiple treatment settings. To comprehensively review the clinical efficacy, safety, and optimal use of romiplostim in the treatment of SAA, based on data from clinical trials, real-world studies, and pediatric case series. A systematic literature search was conducted in PubMed, Web of Science, and Scopus through March 2026 using keywords related to "romiplostim" and "severe aplastic anemia." Studies included prospective trials, retrospective cohorts, and mechanistic studies reporting hematologic response, transfusion independence, and adverse events in SAA patients treated with romiplostim. Romiplostim demonstrated consistent efficacy across pediatric and adult populations in 19 studies involving more than 390 patients with severe aplastic anemia. Hematologic response rates ranged from 41% to 95%, with trilineage recovery observed in up to 55% of patients. High-dose regimens (10-20 µg/kg/week) and early initiation were associated with superior outcomes, particularly in eltrombopag-refractory cases. Long-term use was well tolerated, with low rates of clonal evolution or serious toxicity. Romiplostim is an effective and safe therapeutic option in SAA, particularly in patients who are refractory to or intolerant of standard therapies. Its integration into frontline and salvage regimens offers the potential for durable trilineage responses and transfusion independence. Further studies are needed to define its role in combination strategies and optimal dosing and duration of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.